title: A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
abstract: Standard treatment of advanced ovarian cancer is a combination of surgery and chemotherapy. Additional therapies using the i.p. route are considered as a potential means of improving the locoregional control rate. This Phase II study evaluated the efficacy of i.p. radioimmunotherapy (RIT) in patients with minimal residual ovarian adenocarcinoma after primary treatment with surgery and chemotherapy. Between February 1995 and March 1996, six patients with residual macroscopic (<5 mm) or microscopic disease as demonstrated by laparotomy and multiple biopsies received i.p. RIT. All had initial stage III epithelial carcinoma and were treated with debulking surgery and one line (four patients) or two lines (two patients) of chemotherapy. RIT was performed with 60 mg of OC 125 F(ab')2 monoclonal antibody labeled with 4.44 GBq (120 mCi) of 131I injected 5-10 days after the surgical procedure. Systematic laparoscopy or laparotomy with multiple biopsies performed 3 months after RIT in five patients (clinical progression was seen in one patient) showed no change in three patients and progression in two patients. Toxicity was mainly hematological, with grade III neutropenia and thrombocytopenia in two patients. Human antimouse antibody production was demonstrated in all six patients. This study showed little therapeutic benefit from i.p. RIT in patients with residual ovarian carcinoma.
authors.affiliation: Centre René Gauducheau, Nantes, France.
authors.forename: M A
authors.initials: MA
authors.lastname: Mahé
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
authors.forename: M
authors.initials: M
authors.lastname: Fabbro
authors.forename: J P
authors.initials: JP
authors.lastname: Guastalla
authors.forename: P
authors.initials: P
authors.lastname: Faurous
authors.forename: P
authors.initials: P
authors.lastname: Chauvot
authors.forename: L
authors.initials: L
authors.lastname: Chetanoud
authors.forename: J M
authors.initials: JM
authors.lastname: Classe
authors.forename: P
authors.initials: P
authors.lastname: Rouanet
authors.forename: J F
authors.initials: JF
authors.lastname: Chatal
mesh_terms: D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D051379:Mice; D008875:Middle Aged; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy
chemical_list: D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes